Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients

Core Insights - Pfizer and Astellas' drug Padcev, when combined with Merck's Keytruda, has been shown to significantly reduce the risk of tumor recurrence, progression, or death in patients with a specific type of bladder cancer [1] Company Developments - The collaboration between Pfizer and Astellas focuses on enhancing treatment options for bladder cancer patients through the combination therapy of Padcev and Keytruda [1] - Merck's Keytruda continues to play a crucial role in cancer immunotherapy, complementing the effects of Padcev in this treatment regimen [1]